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Abstract 
3D Printing, an old concept, is today more important than ever. This technology offers 
transformative advantages at every phase of creation, especially within the emergence of 
the term 3D Bioprinting. This work focuses attention exactly on the additive 
manufacturing of human’s organs, reflecting high potential paradigms behind of this 
specific technology in the Portuguese overview of the subject. 
The premise of three dimensional Bioprinting comes from the possibility, to create 
exclusively with the purpose of design functional human organs, by allying three-
dimensional Bioprinting technology with stim cells. The goal is definitely to build living 
human tissues that can function exactly like the native tissues each human has. 
It opens a large amount of assumptions, constrains, problems but at the same time 
solutions come along, this advanced technology is always one step ahead day after day. 
The main purpose of this dissertation is to analyze the many variables associated with this 
technology, considering the context and perceptions of the Portuguese Medical 
Universities. 
Trying to separate fictional from reality of 3D Bioprinting is very hard, to establish 
ambitious goals but yet realistically goals is extremely tough when discussing a subject 
such this one. 
Many of the results from this dissertation can be seen as simple predictions of the future. 
However, 3D Bioprinting can be defined as disruptive type of Innovation, so it is only 
fair to mention the possibility to be a breakthrough in the Medical procedures.       
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Resumo 
Impressão 3D um conceito antigo, é hoje mais importante do que nunca. Esta tecnologia 
oferece vantagens transformadoras em todas as fases da criação, especialmente a quando 
o surgimento do termo “3D Bioprinting”. Este trabalho focaliza a atenção exatamente 
sobre a fabricação aditiva de órgãos humanos, refletindo os elevados paradigmas 
potenciais por de trás desta tecnologia específica no panorama Português. 
Com a premissa do “bioprinting tri-dimensional” aparece a possibilidade exclusiva de 
concretizar o ambicioso propósito de criação de orgãos humanos funcionais, conciliando 
células estaminais com a tecnologia “3D Bioprinting”, cujo objetivo final será a 
construção de tecidos humanos vivos, que poderão funcionar precisamente como os 
tecidos nativos que cada ser humano possui. 
“3D Bioprinting” partilha enorme quantidade de suposições, constrangimentos, 
problemas, mas ao mesmo tempo cria-se novas soluções para problemas existentes, esta 
tecnologia avançada está sempre um passo à frente a cada dia que passa. O objetivo 
principal desta dissertação é analisar as muitas variáveis associadas com esta tecnologia 
tendo em conta o contexto e perceção dada pelas Universidades de Medicina Portuguesas. 
É muito difícil separar ficção da realidade na questão do “3D Bioprinting”, 
principalmente se estabelecemos metas ambiciosas, mas ainda de forma realista tornando-
se extremamente complexo quando se discute um assunto como este. 
Muitos dos resultados desta dissertação podem ser vistas como simples previsões do 
futuro, “3D Bioprinting” pode ser definido como um tipo de rutura de Inovação, e por 
consequência é adequado mencionar a possibilidade de ser um grande avanço nos 
procedimentos médicos. 
 
Palavras-chave: 3D Bioprinting; Orgãos humanos; Inovação; Portugal; Estudantes de 
Medicina.  
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Introduction 
3D Printing is an innovative technology, allied to health field in which the term 
“Bioprinting” emerged, leading to a new type of mentality. Nowadays, there are many 
reasons to believe that in the near future this technology can show up as a revolutionary 
saving-life tool. The improving quality of life might change overnight and become the 
most important forthcoming goal (Mironov et al., 2008). 
The purpose of this dissertation will be the study of the potentials of 3D bio-printing 
technology, highlighting the reproducing of 3D human’s organs (Seedhouse, 2014), 
integrating scientific concepts lectured on the Master in Innovation and Technology 
Entrepreneurship at FEUP (Faculty of Engineering of University of Porto, Portugal). 
Furthermore, it aims to investigate the assumptions that can distinguish the frontier 
between reality and fiction (Guillemot, Mironov, Nakamura, 2010). In addition, there is 
an opportunity to demystify the idea that not always the artificial is malicious to the health 
and in this case it is quite the opposite it can actually save lives   (Lipson et al., 2013). 
Imagine, in short term, the possibility of having fast and efficient answer to a transplant, 
(Nakamura, 2010) avoiding long waiting lists and the dependence of compatible donors, 
since the organs are custom made to fulfil patients’ needs; or perhaps a baby that had the 
misfortune to be born with some heart condition. “On 2011 the surgeon and regenerative 
medicine pioneer, Dr. Anthony Atala gave a talk at the Annual TED conference”, where 
he demonstrated on stage a special 3D printer that was building a prototype human 
kidney. He explained that the increasing health crisis that is arising as people live longer 
and organ failure becomes more common. In fact, one of the biggest problems that 
mankind have these present days, is to really find a compatible organs transplant for the 
growing number of patients and diseases (Barnatt, 2013). 
3D Bioprinting could be the answer to solve many problems, with endless opportunities. 
This technology can express much more than a simple life change, it represents a 
disruptive or radical type of innovation (Dewar, and Dutton, 1986) which includes the 
studying of a new market, new assumptions, and new knowledge in different sectors. 
This opportunity emerges to contextualize the Portuguese market, allowing a new 
biomaterial paradigm, enabling to understand if it is possible the development of a market 
plan highlighting advantages and disadvantages as well feasibility concerns. 
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This study contributes mainly at empirical scientific level, not excluding the possibility 
of any forthcoming gaps in Portuguese dimension for this specific sector. Firstly it will 
use several databases in which are included scientific studies, articles and books that were 
already been published to do a literature review. Then, it focuses on additive 
manufacturing (AM) of human organs. AM is defined as the “process of joining materials 
to make objects from 3d model data, layer upon layer, as opposed to subtractive 
manufacturing methodologies, such as traditional machining”- (Atala, 2009). Beyond this 
it is quite obvious the need to create a survey as one of the most important methodology, 
to share several points of views inside of the medical community, keeping in mind the 
Portuguese dimension in terms of market for this kind of technology inputs. 
Nowadays much of this technology is still in laboratory, but as far as one can see, 
gradually many real-cases have been reported that may easily explain how important is 
to look forward. If today it is possible to save a baby with a simple 3D modelling 
procedure, what can be achievable in 10 or 20 years?  
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1. Literature review 
1.1. Innovation 
Innovation has been frequently used to express the application of better solution that 
encounters new requirements, and it can be accomplished through product, processes, 
services, technology or ideas. “The notion that innovation begins with a discovery in 
“basic science” proceeds with an application or invention derived  from this fundamental 
work (“applied science”) and ends with the development of a new product or process (an 
“innovation”) was indeed at one time quite influential.” (Freeman, 1996). 
Furthermore “innovation is the specific tool of entrepreneurs, the means by which they 
exploit change as an opportunity for a different business or service. It is capable of being 
presented as a discipline, capable of being learned, capable of being practiced”. (Drucker, 
1985). The implementation of a technology by itself often requires solving complex 
problems. Schumpeterian literature usually refers that “entrepreneurs will seek to use 
technological innovation – a new product/service or a new process for making it – to get 
strategic advantage. Joseph Schumpeter called it “monopoly profits”, and usually refers 
that innovation is a process not an event which means there is an opportunity to see what 
has been done and try to imitate it – with the result that other innovation emerges. 
Schumpeter “talks of a process of ‘creative destruction’ where there is a constant search 
to create something new which simultaneously destroys the old rules and established new 
ones – all driven by the search for new sources of profits” (Schumpeter, 1950). 
Innovation is an important concept to understand and it contributes in different aspects: 
for example, evidence suggests a strong correlation between market performance and new 
products (Souder and Sherman, 1994). Creating innovative products help to capture 
market shares, increasing the profitability in those markets. In case of mature and 
established products, competitive sales growth doesn’t necessary depend only on the price 
but also on non-price factors – design, customization and quality. “Competing in time 
reflects a growing pressure on firms not just to introduce new products but to do faster 
than competitors” (Rosenau et al., 1996) – “Companies achieve competitive advantage 
through acts of innovation. They approach innovation in its broadest sense, including both 
new technologies & new ways of doings things” (Porter, 1990) 
11 
 
Nowadays in terms of technological innovation, appeared a definition called “open 
hardware”. Open source hardware “is about open sourcing innovation, and also 
democratizing innovation, but does not come with 20 years of exclusive rights (Anderson 
et al., 2006). The benefit is that you have an entire community contributing to your 
designs, innovating, and sharing their derivatives to your product. It pushes the original 
designer to create a better product and continue to improve it rather than lock it in a 20 
year stalemate.”(Pearce, 2012). Open source “philosophy” works perfectly for relatively 
complex products, such as software and electronics. Only few people can improve 
someone else’s complex circuit or algorithm, so the original designer usually still stays 
in control of the project even after it is released. As an example of this open source 
“philosophy” and according to Bioprinting subject it is already possible to download a 
portable document file (pdf) denominated “instructable” that teaches how to convert a 
standard inkjet printer into a device that can print out cells. 
“Many great technological innovations that are created for one purpose end up being used 
for another.” (Barnatt et al., 2013) It may be the case of ‘product innovation’, that is, 
changes in the things (products/services) which an organization offers; in addition, there 
may be a ‘process innovation’, meaning there are changes in the ways in which products 
are created and delivered. We can also consider ‘position innovation’, which represents 
changes in the context in which the products/services are introduced; finally, the 
‘paradigm innovation’ refers to changes in the underlying mental models which frame 
what the organization does”.(Tidd and Bessant, 2013) 
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1.2. Emerging Technology  
Why some technologies shake up the world while others doesn’t affect our daily live 
often? (Anderson, 2008) Burst of innovation take place when an emerging technology 
removes a once prohibitive barrier of cost, distance or time. In the case of (e.g.) 3D 
printing, it shrinks two prohibitive costs to zero: the cost of customization and the cost of 
complicated shapes. 
Emerging technology is distinguished from the conventional technology; (Scheufele and 
Lewenstein, 2005), “acquiring preemptive knowledge about emerging technologies is the 
best way to ensure that we have a say in the making of our future” (Mota, 2012); Emerging 
technologies can be defined by highly capability of technical innovation which represents 
progressive developments within a field for competitive advantage. (Lewenstein et al., 
2005) 
Technology can help target and qualify the emerging markets and it is often related to 
create the perfect conditions, tools and concepts while this term “emerging technologies” 
is still used without a clear meaning or definition. 
 Emerging technologies are evolving organisms that experience hype cycles, while at the 
same time being potentially disruptive, not yet fully understood, and not yet fully 
researched. (Veletsianos, 2010). The impact of technological innovation and 
advancements have brought massive social change (Gazit and Cooper, 2011). “What is 
discontinuous about the moment of radical technological change? Discontinuity typically 
does not lie in a radical advancement in technology itself; rather, the discontinuity stems 
from a shift of an existing technical lineage to a new domain of application. Seeming 
revolutions such as wireless communication and the internet did not stem from an isolated 
technical breakthrough”. (Adner and Levinthal, 2002). “The implementation of new 
technologies, products, or business models that represent a dramatic departure from the 
current state of the art in the industry” (Bessant et al., 2006). 
Emerging technologies are contemporary advances such as the example of Innovation; it 
can also be characterized as a process not a invent – “One of the problems in managing 
innovation is variation in what people understand by the term, often confusing it with 
invention. In its broadest sense the term comes from the Latin – innovare – meaning ‘to 
make something new’. Innovation is a process of turning opportunity into new ideas and 
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of putting these into widely used practice” (Wilson and Stokes 2010). Emerging 
technology needs innovation to survive. (Porter, 1990). 
“Emerging markets and emerging technologies present challenges and opportunities for 
businesses and individual entrepreneurs who focus their firms for competitive advantage 
on them” (Tidd and Bessant, 2012).  
3D Bioprinting definitely may be seen as an emerging technology for constructing and 
fabricating artificial tissue and organ constructs. “This technology surpasses the 
traditional scaffold fabrication approach in tissue engineering (TE).  
Currently, there is a lot of research / investigation (e.g. Atala, 2011) being done on 
Bioprinting technology and its potential as a future source for implants and full organ 
transplantation. (Forgacs et al., 2012). Once more this emerging technology appears to be 
more promising for advancing tissue engineering, toward functional tissue and organ 
fabrication for transplantation, looking forward in order to save lives. (Ozbolat and Yu, 
2013)  
1.3. Time to Market 
What does “time to market” mean? Usually it defines the period of time it takes from a 
product being conceived until it is being available for sale (Kenneth, 2004). Timing of 
market entry is a critical decision, involving the need to make a distinct premeditation 
and balance the risk of premature entry with the problems of missed opportunities as a 
result of late entry (Lilien and Yoon, 1990; Castro and Chrisman, 1995). 
“Predicting future markets for the 3D technology printed goods and services is an equally 
daunting task. It is difficult – almost impossible – to offer a few crisp words that sum up 
potential new business models that offer good, fast and cheap products or services to their 
customers” (Lipson and Kurman, 2013). 
A few decades, it may become possible to use a Bioprinter to drastically, quickly and 
fairly safely transform the human body (Atala; 2012; Bernatt 2013). Many questions can 
be answered: (e.g. Dr. Atala conference, 2011). “Want bigger muscles without exercise? 
Then why not visit your local Bioprinting clinic and have them printed into your body 
that afternoon? Or fancy going skiing but worried about breaking your legs? Then why 
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not have your bones replaced with new one that features carbon nanotube enforcements? 
These top-of-head scenarios may sound both fantastical and scary. Yet they may well be 
just the tip of a cosmetic Bioprinting iceberg”. (Barnatt et al., 2013)  
The fact that Bioprinting is now both a hobbyist and professional pursuit does strongly 
suggest that more concepts can emerge (Barnatt, 2013).  
In 2014 there are currently “123.175 people waiting for lifesaving organ transplant only 
in United States of America (U.S.). Of these, 101.170 await kidney transplants, on 
average nearly 3,000 new patient are added to the kidney waiting list each month. 12 
people die each day while waiting for a life-saving kidney transplant, every 14 minutes 
someone is added to the kidney transplant list. In 2013, 4.453 patients died while waiting 
for a kidney transplant” (National Kidnay foundation, 2014). In Portugal by the end of 
2014, there were 1970 patients waiting for surgery, the number of new patients on the 
waiting list for kidney nearly double last year. “Portugal, along with Turkey, is the 
country that has the highest rate of new patients.” (Newsletter Transplant, 2015) 
The newsletter of the Council of Europe places Portugal in the fourth place in the organ 
searching and in the 10th place in transplantation. In 2015, 81 patients died while waiting 
for the transplants, 43 died waiting for a compatible kidney. “The kidney transplantation 
face several problems, beside the increase of patients, there is less use of harvested 
organs.” (Portuguese Institute of Blood and Transplant, 2015) 
The fast appearance of commercially Bioprinters can be definitely considered one of the 
most remarkable developments of the past decade. The exponential progression of 
different deviations of Bioprinting technology resembles the early development phase of 
“AM (Additive Manufacturing) technology two decades ago, when many competing 
technologies were developed but not all of them were successfully commercialized (Atala 
et al., 2012). Robotic Bioprinters are already commercially available, while others are 
still under development. The 3D Bioprinters currently on the market can cost around 
$100–200 thousands, depending on their unique capabilities, while 3D homemade 
Bioprinters can cost less than $20 thousands” (Ozbolat and Dababneh, 2014). 
As some authors referenced, the success behind emerging technologies comes from 
“looking at existing emerging technologies and pay particular attention to market niches 
that will accept the technologies in their present form”.(Adner, 2002) -“Deploying 
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emerging technologies in these early markets can be a means of both realizing profits in 
the near term and providing valuable feedback regarding the demand for possible 
attributes of technical functionality to support and guide their further development.”- 
(Adner, Levinthal, 2002) 
Entrepreneurs have an important duty related with the introduction of new technologies 
in the market. (Gruber and MacMillian, 2007). “Technologies are often configurable to 
serve a variety of different markets, it is possible for entrepreneurs to identify multiple 
market opportunities prior to the first market entry of their emerging firms, and if they 
elect to do so, they therefore have a choice of which market to enter first”. (Thompson, 
et al., 2007) 
1.4. The Beginning of 3D Biopriting as creative disruptive technology 
“3D Bioprinting has emerged to change the world” (Seol, Kang, Lee, 2014). It has many 
times been referred from several authors, as powerful tool for building tissues and organ 
structures (Atala et al., 2011) in the field of Biotechnology Engineering. Gabor Forgacs 
was one of the pioneers of this technology in 1996. Following a study of chicken embryos, 
he noticed that cells stick together during the embryonic development in a manner which 
makes perfect sense to assist in artificial tissue fabrication (Barnatt, 2013). 
Alongside Gabor Forgacs, there is several others highly significant Bioprinting pioneers 
such as Makoto Nakamura -following the increasing number of patients desperate for an 
organ transplant (Ozbolat, 2013), Nakamura started to conjecture hypothetical way to 
offering hope for bridging the gap between organ shortage and transplantation needs. He 
begun by creating mechanical, inorganic prosthetics and “quite by chance he realized that 
the droplets of ink emitted from the print head in a standard inject photo printer are about 
the same size as human cells”. So basically he just needed to turn a photo printer into a 
3D Bioprinter using perhaps human cells as the “special ink” for the machine. In theory 
the process was complex but at the same time easy to understand. The printer could output 
the cells via a material jetting process that would eventually result in artificial, living 
tissue (Mironov, Boland, Tirusk, 2003). However, “the first experience in standard Epson 
photo printer” did not work as “the device’s print head simply clogged up”. It was 
necessary to modify the photo printer to successfully output cells that survived the inkjet 
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printing process. This was “achieved by encasing the cells in solidus alginate to stop them 
from dying out, and by jetting them into a calcium chloride solution”. 
In addition to Nakamura and Forgacs, others researchers have managed to adapt standard 
inject printer mechanisms to demonstrate proof- of-concept Bioprinting. In this context, 
Thomas Boland and Vladimir Mironov were possibly some of the most notable 
researchers, having successfully conducted similar experiments. 
The first commercial Bioprinting- NovoGen MMX- was developed by Gabor Forgacs, 
who founded in 2007 a company, called Organovo, with the mission to “create tissue on 
demand for research and surgical applications”. Two years later the MMX just needed 
sample of cells to be sourced from a patient biopsy or stem cells in order to have final 
volume of cells. Let us explain this technique more carefully: “ For example if a blood 
vessels is to be Bioprinted, an aggregate is created containing a mix of primary endothelial 
cells (which form the lining of blood vessels), smooth muscle cells (which allow blood 
vessels to expand and contract) and fibroblast (which form tough connective tissue) then 
the procedure is to compress like a kind of bio-ink “sausage” allowing an “aggregate 
cutter” to chop this sausage into bits, with the very tiny pieces spontaneously forming 
into bio-ink spheroids, each one containing between 10,000 and 30,000 individuals cells” 
(Gabor Forgacs et al., 2009). In December 2010, Organovo used NovoGen MMX to 
create the first Bioprinted human blood vessels while in the same year “Time Magazine” 
heralded the NovoGen MMX as one of the best inventions. Three years later it even 
reported the successful of Bioprinting human liver tissue. Organovo is considered one of 
the world´s 50 most innovative companies. It is already a publicly traded company, one 
of the only five 3D printer manufacturers of any genre to have this status.  
Furthermore aggressive procedures such as replacement of entire soft-tissue organs, like 
kidneys or livers, can be possible, once Bioprinted patches and grafts enter clinical 
practice (Atala and Forgacs, 2012). The prediction for that to happen, as Dr. Atala and 
Professor Forgacs referred, it can be possible in 2018. 
Many authors referenced the solution of turning a common 3D photo printer to 
Bioprinting, happened by quit chance,(e.g Nakamura and Forgacs, 1996) after all it turns 
to be one solution to probably solve several problems mainly related with organs 
transplant.(Atala et al., 2011). However one of the biggest barriers for that to happen is 
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the slow development of new drugs by the pharmaceutical companies, worldwide trials 
of next generation medicines are increasingly failing, labs frequently not living up to 
expectation, and also difficulty to find shareholders willing to give money for this kind 
of innovation. 
A range of Bioprinting and related hardware has been developed, based at the Advanced 
Tissue Biofabrication Center at the Medical University of South Carolina, US. Mironov 
believes that any future Bioprinted heart will need significant workout in the lab by an 
appropriate machine before it is strong enough to pump blood around a human body just 
like the muscles, they become stronger as a result of exercise. 
It is important that the technology is available in such a way that everyone can access to 
it when needed. In fact, some authors believe Bioprinting organs for human transplant 
shall be easy to be fabricated “at the click of a button” (Ozbolat Nakamura et al. 2012) 
which means that there should be an integrated friendly user interface software. 
“Systems must be developed to transport nutrients, growth factors and oxygen to cells 
while extracting waste so that the cells can grow and fuse together, forming the organ. 
Cells in a large 3D organ structure cannot maintain their metabolic functions without this 
ability, which is traditionally provided by blood vessels” (Ozbola, 2012). The problem 
that must be overcome is the difficulty to Bioprint “microfluidic channels” that can take 
on the natural vascular network. Bioprinting a pancreatic organ that is glucose sensitive 
can be a good example (Forgacs, 2009) of how complex and hard is to perform this 
activity. It is expected in the medium-term to transplant such a Bioprinted organ into an 
animal to successfully “hook it up to its vascular system”. In long-term the wish is to 
develop the “ultimate economical and feasibility technology” (Seol and Kang, 2014), 
allowing stem cells to be used, to Bioprinting a pancreatic organ that can be successfully 
transplanted to a human body, including the possibility of regulating the glucose level of 
the blood. 
It is essential to make a distinction between additive manufacturing and rapid prototyping. 
(Petrick and Simpson, 2013). Both this terms refer to turn computer models into real solid 
objects by building with many thin layers (Barnet et al., 2013), but while rapid prototype 
is already been used for at least the last 30 years (creating concept of models or mold 
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masters), the application of this technology has been starting to widen to different sectors 
and so it appears the term additive manufacturing.      
Many researchers worldwide share the belief that one day Bioprinting will result in a 
medical revolution allowing for the true meaning of disruptive technology. (Markwald 
and Forgacs, 2003; Bartolo and Jorge, 2007; Mironov and Boland, 2012) 
Despite the enormous progress that assisted and many breakthroughs of the last decade, 
3D Bioprinting technology is not mature enough, which means that it has met several 
challenges and limitations. Firstly, there is the problem of “repeatability, cell viability, 
practicality, and biocompatibility of Bioprinting processes cell density”. There are also 
technical problems regarding the “cytotoxicity, bioprintability, solidificability and 
solidification speed, mechanical and chemical properties, affordability and abundancy, 
and cell viability and long-term cell functionality of bioinks compactness”. In addition, 
there are issues related with “accuracy, high-degree-of-freedom motion capability and 
motion speed, commercial availability, full-automation capability, user-friendliness, 
sterilibility, affordability, and versatility of the bioprinters” (Dababneh and Ozbolat, 2014) 
2. Methodology  
This chapter presents and describes the methodological options, such as the research 
method and tools, the questionnaire design and formulation of the data collection process. 
2.1. Identification of methodology and applied framework 
It is relevant to understand how this technology can be applied to the daily life. To better 
understand this point it was required a test in the field. Based on the literature review, it 
was created a quantitative survey targeting all medical students in Portugal. The main 
goal here is to see how they react to the context and the meaning of this technology, 
considering the implications of it in the medical activity.  
In order to achieve such an ambitious goal, it was needed the participation of 8 Medical 
University in Portugal, precisely 241 students participated in the survey and many others 
had the curiosity to try to understand what in fact 3DBioprinting is all about. The target 
of this survey was restricted only to the Medical Students in Portugal; however some of 
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the Erasmus Students (foreigners) did also answer the questionnaire but unfortunately the 
results from this were not meaningfully relevant to the case. 
Quantitative methodology applied on this subject has been defined with the help from 2 
main research questions:  
 The first one related with the use of the 3DBioprinting in what terms and for what; 
 The second related with the level of acceptance from the medical perception; 
Several questions were asked in terms of the application of this technology and the most 
interesting results come from 2 main questions: if the “3D Bioprinting could be the 
answer for Transplants” or if the “3D Bioprinting could be the answer for new drugs 
investigation”.  
Table 1 groups the questions of the survey in 3 categories: awareness, application and 
expectation, each of whom will be discussed in the following section. The complete 
survey is presented in appendices 1 and 2. 
 
Research question 
The most relevant questions (Q) of 
the survey 
Proposed analysis technique 
3DBioprinting 
Awareness Q8,Q9,Q20 
Frequencies, correlations and 
appropriated tests 
Application 
Q10,Q11,Q12,Q14,Q17 
Expectation Q13,Q15,Q19 
Table 1 - Schematic of analysis statics 
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Figure 1 - Distribution by University and Gender 
The ages of the participants are between 18 and 49 years, in which the average age is 
24,21 and 4,33 is the standard deviation; 76 (31,5%) were male students and 165 (68,5%) 
female students, reaching the total of 241 surveyed. Figure 1 presents the number of 
answers by gender (female and male) in each university and the repartition of answers 
among Medical Portuguese Universities:  
 FMUP (Faculty of Medicine of University of Porto)  
 ICBAS (Institute of Biomedical Sciences Abel Salazar of U. Porto)  
 UA (Algarve University)  
 FMUM (Faculty of Medicine of University of Minho)  
 FMUL (Faculty of Medicine of University of Lisbon)  
 FMUC (Faculty of Medicine of University of Coimbra)  
 FCML (The Faculty of Medical Sciences of Lisbon)  
 FCSUBI (Faculty of Health Sciences of the University of Beira Interior)  
 Other ( Represent foreigners studying in Portugal at that moment) 
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Figure 2 - Distribution of Students by Academical Year 
 Figure 2 refers to the repartition of the participants by Academical year. Considering this 
categorization, students who participated more, are part of the first years of the course, 
which can be classified as students from the integrated Master of Medicine. Therefore, 
through this chart, it is possible to make the division between 2 large significant groups: 
integrated Master of Medicine with the total of 80,5% of the answers and 19,5% 
belonging to students attending the common year, specialty, and other higher levels.  
2.2. Data collection  
The survey was sent to all the Portuguese Medical Universities by using the email 
miet1300706@fe.up.pt, addressed directly to the students. In the case of FMUP, it was 
done through the SIGARRA system, which allows students from the University of Porto 
to use the dynamic email. The others faculties do not use the same system, consequently 
the method used was more formal: by telephone and through the institutional email. In 
addition, it was used the Google Forms platform to insert the questionnaire. 
The submission initiated in April 30th, 2015, requesting response via Google forms 
platform, until the 1st of June. However, by that date, the reply was manifestly insufficient, 
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so it was required the help from the social networks such as Facebook and Twitter, and 
also a new email/phone request was sent in 1st of June with a new deadline (the 1st of 
August, 2015). 
Although it would be interesting to have a higher number of answers, further attempts to 
have extra observations were not fruitful. Therefore, it was necessary to move on with the 
sample existed until the moment, which consists of 241 students, the majority of which 
from the north of Portugal. Figure 3 summarizes the process of data collection.  
 
 
The data was collected by survey and then analyzed statistically by “IBM SPSS 
Statistics” software. 
 
 
Figure 3 – The process of Data Collection 
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2.3. Sample 
There are 8 Medical University in Portugal according with ANEM (Portuguese 
Association of Medical Students) 12.000 students are currently enrolled in the Integrated 
Master of Medicine (2015/2016). Table 2 presents the number of students in the sample 
by institution. 
University Sample 
FMUP 117 
FMUL 10 
ICBAS 49 
FMUC 10 
FCML 4 
FMUM 10 
FCSUBI 2 
UA 25 
OTHER 15 
Table 2 - Sample 
3. Results 
This chapter presents and describes the statistical analysis of the survey through the SPSS 
statistics software, which is distributed by 3 main sections: Awareness, Application and 
Expectation. 
As mentioned before, the research tool applied was the survey and it is used to: obtain 
knowledge of a population, its thoughts and actions; to analyse a social phenomenon 
through collected data about individuals of the population; in cases where it is essential 
to study a large number of people (Quivy and Campenhoudt, 2005). As a result this 
research tool aids this dissertation purposes. 
The survey (see Appendices 1 and 2) was developed in Portuguese and in English, 
considering the target surveyed. It is possible to comprise the survey in 2 parts. The first 
part addresses the description of the people surveyed: Gender, Age, which university they 
are attending including the years and medical speciality if appropriate.  
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The second part addresses the main research questions wherein includes the Awareness, 
Application and Expectation. 
The survey presents: closed-ended questions, which can be categorized as either single 
questions related to respondents description (where one response is required), 
dichotomous (where two response items are provided) and multichotomous (where 
several choices are listed); it also uses a scaled-response questions, in which a scale to 
measure the attributes is used. 
3.1. Awareness 
The “Awareness” concerns to the knowledge about this technique from the person 
surveyed perspective. It includes 3 main questions (see Appendix 1 or 2). 
 
Have you ever heard about 3D Bioprinting? 
 Frequency Percent Cumulative Percent 
 No 74 30,7 30,7 
Yes 167 69,3 100,0 
Total 241 100,0  
Table 3 – Frequency table  
The first question aims to know whether students are familiar with the concept of 3D 
Bioprinting. One hundred and sixty seven of the 241 surveyed (69.3%) claim to be 
knowledgeable of 3D Bioprinting. The remaining 74 surveyed (30.7%) answered that 
they does not know about technology, as presented in table 3.  
In table 4 we present the distribution of answers by gender  and in table 5 we conduct a 
chi-square test to understand the possible correlation between 2 variables, “gender” and 
the question (“Have you ever heard about 3D Bioprinting”) 
    
 Have you ever heard about 3DBioprinting? Total 
 No Yes  
Gender? Male 24 52 76 
Female 50 115 165 
Total 74 167 241 
Table 4 – Cross tabulation 
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Test Chi-square 
 Value df Level of Sig. Sig.  2 Sig. 1  
Chi-square Pearson ,040 1 ,842   
Fisher test    ,881 ,478 
Number of the case 241     
Table 5 - Chi-square test 
Considering the results of the Chi-square test, given by a p-value greater than 0, 05, there 
was not any statistically significant relationship between gender and that question. The 
highest number of participants surveyed in terms of gender are female with 165 and only 
76 for male participants. The level of awareness about 3D Bioprinting as the table refers 
is positive for both between females and males. 
In the second main question, we try to understand how the students came across with 3D 
Bioprinting.  
 
                                                Figure 4 - Circle Graphic 
 
Figure 4 presents the answers to this question. It is clear the most source of knowledge is 
from Tv and Internet, representing 49,3% of the answers. It was interesting to realise that 
the information in the class correspond only 12,9%, according to the survey. One of the 
reasons that could explain this low percentage may be because the subject in question is 
very uncommon inside the medical Universities in Portugal. The second higher source of 
knowledge is coming from books, newspaper and magazines, representing 24,5% of the 
answers.  
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The last main question in the section of “Awareness” is: -“From your point of view does 
3D Bioprinting can be replaced by any other technology? If your answer is yes, please 
refer which one?” 
 
Table 6 presents the results. In fact, 86,7% of the respondents does not believe any other 
existing technology replace 3D Bioprinting, however the last 13,3% of the surveyed 
mentioned diverse “replacing” technologies, nevertheless many of them can still be used 
as a complement of 3D Bioprinting technology by itself. Tissue culture and tissues from 
animal origins was the highest mentioned replacing technologies mentioned by the 
respondents. 
 
 
From your view does 3D Bioprinting 
can be replaced by any other 
technology? 
Total 
No. 3D Bioprinting 
is completely 
innovative Yes 
Analysis by age range 18-20  44 3 47 
21-23  61 11 72 
24-26  59 11 70 
27-29  26 2 28 
>=30 19 5 24 
Total 209 32 241 
Table 7 - Cross tabulation 
Table 7 details this answer by age and table 8 refers to the analysis between 2 variables: 
Age range and the question above. The main purpose was to execute a test of chi-square 
to understand if there was any relationship between these 2 qualitative variables. 
 
 
 
Table 6 - Frequency table 
 Frequency Percent Cumulative Percent 
 
No 209 86,7 86,7 
Yes 32 13,3 100,0 
Total 241 100,0  
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Test chi-squad 
 Value df Significance level 
Chi-Squad Pearson 4,656 4 ,324 
Number of cases 241   
Table 8 - Chi-square Test 
Considering the results of the Chi-square test the significance level p = value > 0, 05 there 
was not any statistically significant relationship between age and the question above. 
Between 21 till 26 group of ages, we record the highest number of answers and from this 
point of view there was not any relevant discrepancy reported. 
3.2. Application 
The Application concerns to where this technology can actually be used. It includes 5 
main questions with relevant content. (See Appendix 1 or 2) 
Analysis by age range * 3D Bioprinting could be an answer for Transplants? (Q10) 
 
 
3D Bioprinting could be an answer for Transplants? 
Total Nothing 
Important 
Less 
Important 
Little 
Important 
Some 
Important 
Important 
Very 
Important 
Analysis by 
age range 
18-20 0 1 4 7 18 17 47 
21-23 3 5 6 22 16 20 72 
24-26 1 6 11 7 27 18 70 
27-29 0 4 1 5 13 5 28 
>=30 0 0 1 12 8 2 23 
Total 4 16 23 53 82 62 240 
Table 9 - Cross tabulation 
A question was asked mainly to understand if 3D Bioprinting could be the answer for the 
Transplants, which by itself it is a huge problem that Humanity has to face, with tendency 
to increase each year. It was necessary to do a scaled-response questions, in which we use 
a scale to measure the attributes of the construct, from “Nothing Important” till “Very 
important”. Our goal is to have the opinion of the respondents about the importance of 
the application of the 3D Bioprinting for organs transplant. The answers are reported in 
table 9. A vast majority of students consider that 3D Bioprinting is important to solve the 
problem.  
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In order to do the Chi-square test it was decided to cross Age and the question above to 
see if there any statically significant relationship between them.  
 
Test chi-square 
 Value Df Significance level 
Chi-square Pearson 41,460 20 ,003 
Number of cases 241   
Table 10 - Chi-square test 
Table 10 presents the results. In fact, the p-value is less than 0,05, suggesting that both 
groups are different from each other. It can be noticed a statistically significant 
relationship between age and level of trust about 3D Bioprinting being an answer for 
transplants. Nevertheless it is important to refer the high number of people that have 
confidence in the importance related to the application of 3D Bioprinting directed to the 
transplant of organs. While 34% of the respondents answered “Important”, 25, 7 % 
considered it to be “Very Important”. Only 1, 7 % of the people surveyed doesn’t believe 
that 3D Bioprinting could be the solution for the transplants. 
Analysis by age range * 3D Bioprinting could be an answer for new drugs investigation? (Q11) 
 
 
3D Bioprinting could be an answer for new drugs investigation? 
Total Nothing 
important 
Less 
important 
Little 
important 
Some 
important 
Important 
Very 
important 
Analysis by 
age range 
18-20 0 0 1 13 17 16 47 
21-23 1 2 4 14 26 25 72 
24-26 1 3 3 14 23 26 70 
27-29 0 4 0 2 9 13 28 
>=30 0 1 0 9 11 3 24 
Total 2 10 8 52 86 83 241 
Table 11 - Cross tabulation 
The process was repeated concerning now new drugs investigation. In the Question: 3D 
Bioprinting could be an answer for new drugs investigation, 34, 4 % of the respondents 
voted for “Very Important” and 35, 7 % for “Important”, less than 1% doesn’t believe 
that could have that purpose. The results are, therefore, very similar to those obtained in 
the previous question. It is safe to assume that the highest percentage of respondents 
agreed that 3D Bioprinting can be used not only as a solution for transplants but also to 
test or create new drugs (i.e., for investigation purposes).  
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Test chi-square 
 Value Df Significance level 
Chi-square Pearson 26,009 20 ,166 
Number of cases 241   
Table 12 - Chi-square test 
Table 12 presents the chi-square test for the relationship between age and level of 
importance reported in the question. As P-value >0, 05, we find there is no statically 
significant relationship between the variables. 
 
 
Please mention in which situation 3DBioprinting could be an asset? 
Total 
University 
environment 
(Practical 
classes) 
Only for 
Transplants 
Only for 
new drugs 
investigation 
Transplants 
and new 
drugs 
investigation 
None of 
above 
Analysis by 
age range 
18-20 9 4 2 31 1 47 
21-23 14 3 6 45 4 72 
24-26 12 2 5 50 1 70 
27-29 4 2 4 18 0 28 
>=30 6 2 0 16 0 24 
Total 45 13 17 160 6 241 
Table 13 - Cross tabulation 
The state of this technology can be served as a tool for several situations, perhaps the 
most obvious being:  
 University environment perchance practical classes, where the student would be 
able to use printing organs; 
 Like it was mentioned before, a solution for transplants; 
 In case of development of drugs and investigation purposes, the printing organs 
could be definitely an asset (Atala, 2011) 
Table 13 refers the number of the respondents that consider each of these situations as 
more favored to 3D Bioprinting. This question was a multichotomous type of question in 
which several option items were available. However it is important to underline the fact 
that some of the options say “Only”: Example: “Only for transplants”; “Only for new 
drugs, investigation” and the both together. So 18, 7 % of the respondents believe 3D 
Bioprinting is relevant in Universities in practical class; 5, 4% have confidence it will be 
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used “Only” for transplants; 7,1% consider that it will be used “Only” for investigation 
of new drugs; on the other hand, 66,4% of the respondents consider it will be used not 
only in cases of transplants but it is as well a valuable asset to investigation and testing 
new drugs.  
We executed the chi-square test between age of the respondents and the question: “Please 
mention in which situation 3D Bioprinting could be an asset”. The P-value is equal to 
0,701 > 0, 05, meaning there is no statistically significant relationship between the 
variables. It was also tested the chi-square test using the variable gender, for which the p-
value is equal to 0,412 > 0, 05. 
The next question (Question 14 - see Appendices 1 and 2) asks respondents to mention 
possible constrains about 3D Bioprinting. “Human being mentality” in some cases could 
be considered a constraint around this technology explicitly in terms of culture habits. 
Not everyone think the same, which means the technological advance sometimes doesn’t 
inspire trust to certain individuals. Other option included was “Need”. This option means 
the need to find a fast solution to a problem; “bureaucratic processes” were also 
considered as some countries have high bureaucracy systems, which could easily become 
enormous problem for this technology to enter in the market. “Ethics issues” is another 
possibility, mainly by doctors, so it was very important to analyze this variable to 
understand if this is a problem or not for medical students. “Religion” is another option 
as it not always agrees with science and definitely this technology might create some 
controversies. Finally, we consider “Economy” as it certainly will take a very important 
role, since it is important to make investments or no technological advance is ever 
possible. 
The answers to this question reveal that: 
 65, 1% of the respondents does not believe “Human being mentality” can be a 
constrain for 3D Bioprinting;  
 83, 8% of the respondents does not agree that “Need” is a constrain to 3D 
Bioprinting; 
 57, 3% of the respondents does not agree that “Bureaucratic processes” is a 
constrain to 3D Bioprinting; 
 70, 5% of the respondents agree that “Ethics issues” can be a constrain to 3D 
Bioprinting; 
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 75, 5 %  of the respondents does not agree that “Religion” is a constrain to 3D 
Bioprinting; 
 77, 6 % of the respondents does not agree that “Politics” is a constrain to 3D 
Bioprinting; 
 63, 5% of the respondents agree that “Economy” can be a constrain to 3D 
Bioprinting; 
 
Question 17: “Do you agree with 3D Bioprinting in mass production?” 
 
The next question considers the students’ agreement to 3D Bioprinting in mass 
production, as reported in table 14. Why mass production? This is a consideration about 
the application of the 3D Bioprinting. As we know the cost of a single unit (unit price 
principle) can be higher than the aggregation of the product (industry fabrication 
principle). Of course many of the respondents share the same believe around this subject, 
which is the risk of banalization of the 3D Bioprinting process. Also some of them 
mention about the timing, considering that it is not a good idea in the first phase (when 
entering in the Market), but when the process becomes more mature it may be viable. 
Furthermore the risk might be too high in comparison with the benefit. Others referred 
that mass production could be beneficial only for Medical University practical classes. 
3.3. Expectation 
This section contains the prediction about the technology 3D Bioprinting. The questions 
formulated to the students are based on the existing literature. Although it may be 
necessary to do further analyses and take the opinion of the medical community, not only 
in Portugal but also in other countries, the opinions shared by medical students can 
provide some insight regarding the future of 3D Bioprinting. 
 
 Frequency Percent Cumulative Percent 
 No 107 44,4 44,4 
Yes 134 55,6 100,0 
Total 241 100,0  
Table 14 – Frequency table 
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Question 13: “What is your prediction for the 3D Bioprinting technology to be used?” 
 Frequency Percent Cumulative Percent 
 5-10 years 83 34,4 34,4 
20-40 years 135 56,0 90,5 
Next century 18 7,5 97,9 
Never 5 2,1 100,0 
Total 241 100,0  
Table 15 – Frequency table 
The first question (question 13) asks students to predict when 3D Bioprinting will be used, 
as reported in table 15. The results show that 56% of the respondents have confident that 
in the next 20-40 years it will be used; however, 34, 4 % believe that 3D Bioprinting will 
be in the next 5-10 years. Only 7, 5 % of the respondents believe it will be used only in 
next century and merely 2, 1 % stated that will never be used. 
 
Question 15: As a future Doctor, do you agree with the use of 3D Bioprinting? 
 Frequency Percent Cumulative Percent 
 No 8 3,3 3,3 
Yes 233 96,7 100,0 
Total 241 100,0  
Table 16 - Frequency table 
Table 16 considers an interesting question, which is whether, as a future doctor, the 
respondent agrees with the usage of 3D Bioprinting. It is definitely clear the confidence, 
from the Medical point of view, regarding the usage of 3D Bioprinting: 96, 7% of the 
respondents answer favorably to the usage of this technology. 
 
Question 19: Do you agree with this quote “3D Bioprinting is the future of modern 
medicine”? 
 Frequency Percent Cumulative Percent 
 No 96 39,8 39,8 
Yes 145 60,2 100,0 
Total 241 100,0  
Table 17 - Frequency table 
Finally, students are required to answer whether they think that 3D Bioprinting is the 
future of medicine or not. Table 17 presents the results. According to 60, 2% of the 
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respondents, it is possible that 3D Bioprinting will be very relevant in the area in the 
future.   
4.  Conclusion 
This chapter describes an overview of the foremost outcomes of this dissertation, 
answering the research question based in the information provided. On the other hand it 
addresses the contributions of this research and refers opportunities for future research. 
4.1. Final overview and opportunities for future research 
“The world changes materially. Science makes advances in technology and 
understanding. But the world of humanity doesn’t change” (Pierre Schaeffer). The 
literature review tried to describe the current scenario of 3D Bioprinting. Although some 
people may look at it with the feeling of a “utopia” situation, slowly this “utopia” can be 
revealed to be true in the following years. Many real cases already have showed the high 
potentials to become a real technology of the daily-life for each and every human being. 
This dissertation aims to share knowledge about something that may seem unrealistic at 
the present time, but may be a reality in the future. It was all about the passion behind the 
possibility to actually save millions and millions of persons. In fact, the application of 
this technology to organs transplant may not happen in the present but in the future it may 
be the solution. Nevertheless this dissertation tries to evaluate the impact and acceptance 
of this technology by the Portuguese Medical Community, by considering the opinions 
of medicine students.  
It is very clear from the subject by itself that the probability of it being the solution for 
several problems appointed during in the previous chapters is large, but it could also be a 
disruptive type of Innovation with a breakthrough in the medical field. It can employ 
many people all over the world, and certainly creating a specific new Market. 
“Changing the Shape of Medical Research and Practice, Structurally and functionally 
accurate bioprinted human tissue models” that’s the idea behind Organovo, a company 
created exclusively with the purpose of design and create functional human tissues by 
using three-dimensional bioprinting technology. Their goal is definitely build living 
human tissues that can function exactly like the native tissues each person has. As for the 
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business model, it is easy to understand the value proposition, they already have several 
partnerships with biopharmaceutical, academicals medical centers, even now allowing 
researchers to have the opportunity to test drugs on the functional human tissues. 
Without any doubt Organovo is currently doing a great job in order to make the “utopia” 
becoming something real. This American company is not the only company doing such 
astonishing work, there are already a few companies, namely in Europe, trying to 
accomplish the dream. 
In conclusion, there are 2 main Research questions in this dissertation:  
 The first one is related with the use of the 3DBioprinting in what terms and for 
what; 
 The second is related with the level of acceptance from the medical perception. 
These questions are addressed in the methodological and Statistical analysis chapters, 
giving and overview of the Portuguese situation regarding the awareness and acceptance 
of this technology. As limitations, the total number of students that actually participated 
is relatively low and, therefore, this study has to be complemented with further analysis 
in order to clarify in larger detail the results that were obtained. Naturally, it would be 
interesting to do a survey such as the one presented here not only in Portugal, but also in 
other countries, allowing for comparisons.  
So as future research, it would be very interesting to develop a deeper study, using newly 
data, to make comparisons along time and confirm the results. As we know, the technical 
evolution does not stop, it is always evolving each day, and what is nowadays a “utopia” 
can be a reality in the future. The results of this study make us very optimistic in terms of 
the huge chances that 3D Bioprinting has to be a reality applied to the medical world in 
the future. 
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Appendices 
Appendice 1 Portuguese Survey 
  
Emerging technology as new-life style. 3D Bioprinting 
a new era for innovation process 
 
Este inquérito é direccionado apenas para estudantes de Medicina. 
 
Sou vosso colega da Faculdade de Engenharia da Universidade do Porto, estou neste momento elaborar 
tese de Mestrado relacionado com a tecnologia 3D Bioprinting, que poderá ser considerada uma invenção do 
sec: XXI não apenas na Medicina moderna mas como também no "State of Art" do processo de Inovação. 
 
Hoje em dia aliando a base da saúde com a capacidade tecnológica é possível a impressão 3D de tecido 
humano e por sua vez a reprodução através de células retiradas dos pacientes. 
 
O tema vai incidir na reprodução em massa de Orgãos humanos, critérios, previsões, duvidas, tudo isso será 
base de análise em questão. 
 
Sendo assim a sua ajuda é essencial, apenas 5 minutos podem fazer a diferença. 
 
*Obrigatório 
 
1. Género *   
Marcar apenas uma oval.  
 
 Masculino  
 Feminino 
 
2. Idade? *  
 
 
 
3. Indique a sua instituição de Ensino Superior *   
Marcar apenas uma oval.  
 
 Faculdade de Medicina da Universidade do Porto Após a última pergunta desta 
secção, passe para a pergunta 8. 
 
 Faculdade de Medicina da Universidade de Lisboa Após a última pergunta desta 
secção, passe para a pergunta 8.  
 Faculdade de Medicina da Universidade de Coimbra Após a última pergunta desta 
secção, passe para a pergunta 8. 
 
 Instituto de Ciências Biomédicas Abel Salazar Após a última pergunta desta 
secção, passe para a pergunta 8.  
 Faculdade de Ciências Médicas da Universidade Nova de Lisboa Após a última 
pergunta desta secção, passe para a pergunta 8. 
 
 Faculdade de Medicina da Universidade do Minho Após a última pergunta desta 
secção, passe para a pergunta 8.  
 Faculdade de Ciências da Saúde da Universidade da Beira Interior Após a última 
pergunta desta secção, passe para a pergunta 8. 
 
 Universidade do Algarve Após a última pergunta desta secção, passe para a 
pergunta 8.  
 Outra    Após a última pergunta desta secção, passe para a pergunta 7. 
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4. Em que fase de formação se encontra? *   
Marcar apenas uma oval.  
 
 1º ano    Após a última pergunta desta secção, passe para a pergunta 8.  
 2º ano    Após a última pergunta desta secção, passe para a pergunta 8.  
 3º ano    Após a última pergunta desta secção, passe para a pergunta 8.  
 4º ano    Após a última pergunta desta secção, passe para a pergunta 8.  
 5º ano    Após a última pergunta desta secção, passe para a pergunta 8.  
 6º ano    Após a última pergunta desta secção, passe para a pergunta 8.  
 Ano comum    Após a última pergunta desta secção, passe para a pergunta 8. 
 
 1º ano / Especialidade Após a última pergunta desta secção, passe para a pergunta 8. 
 
 2º ano / Especialidade Após a última pergunta desta secção, passe para a pergunta 8. 
 
 3º ano / Especialidade Após a última pergunta desta secção, passe para a pergunta 8. 
 
 4º ano / Especialidade Após a última pergunta desta secção, passe para a pergunta 8. 
 
 Outra    Após a última pergunta desta secção, passe para a pergunta 6. 
 
5. Especialidade (Se ainda não sabe, responda 
"Não sei") *   
Por favor indique qual:  
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
6. Indique outra fase de formação * 
 
 
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
7. Indique outra instituição de ensino * 
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
8. Já ouviu falar sobre a Tecnologia 3D Bioprinting? *   
Marcar apenas uma oval.  
 
 Sim    Passe para a pergunta 9.  
 Não    Passe para a pergunta 10. 
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Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
 
9. Em que âmbito? *   
Marcar tudo o que for aplicável.  
 
Nas aulas 
 
Livros, Jornais, Revistas 
 
Televisão, Internet 
 
Através de amigos,colegas 
 
Outra 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
10. Até que ponto a impressão de orgão humanos poderá ser a resposta para Transplantes *   
Indique a sua importância mediante a escala   
Marcar apenas uma oval.  
 
0 1    2    3    4    5 
 
 
 
 
11. Até que ponto a impressão de orgão humanos poderá ser a resposta para testar novos 
Medicamentos (Investigação) *   
Indique a sua importância mediante a escala   
Marcar apenas uma oval.  
 
0 1    2    3    4    5 
 
 
 
 
12. Mediante as respostas anteriores. Refira em que situação a impressão de orgãos poderá ser 
uma mais valia: *  
Tenha atenção na resposta   
Marcar apenas uma oval.  
 
 Ambiente universitário (aulas praticas)  
 Apenas em relação aos Transplantes  
 Apenas no tratamento de novos Medicamentos (Investigação)  
 Transplantes e testar novos medicamentos  
 Nenhuma das anteriores 
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Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
13. Qual a sua previsão para que Tecnologia 3D Bioprinting seja efectivamente usada *   
Marcar apenas uma oval.  
 
 5-10 anos  
 20-40 anos  
 No próximo século  
 Nunca 
 
 
 
14. As limitações desta tecnologia estão directamente ligadas *   
Marcar tudo o que for aplicável.  
 
Mentalidade do ser humano 
 
Necessidade 
 
Processos burocráticos 
 
Questão de etica 
 
Religião 
 
Politica 
 
Economia 
 
Nenhuma das anteriores 
 
 
15. Como futuro Médico concorda com a utilização da impressão 3D de tecido humano *   
Do ponto de vista da sua aceitação   
Marcar apenas uma oval.  
 
 Sim    Passe para a pergunta 17.  
 Não    Passe para a pergunta 16. 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
16. Indique a razão de não concordar com a 
impressão 3D de tecido humano *  
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
17. Concorda com a impressão 3D em massa *   
Do ponto de vista da sua utilização   
Marcar apenas uma oval.  
 
 Sim    Passe para a pergunta 19.  
 Não    Passe para a pergunta 18. 
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Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
18. Indique a razão de não concordar com a 
impressão 3D em massa *  
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
19. Concorda com a seguinte afirmação " 3D Bioprinting é o futuro da Medicina moderna" *   
Marcar apenas uma oval.  
 
 Sim    Após a última pergunta desta secção, passe para a pergunta 21.  
 Não    Após a última pergunta desta secção, passe para a pergunta 21. 
 
 
20. Na sua perspectiva a utilização desta tecnologia poderá ser substituta de outra tecnologia já 
utilizada *   
Marcar apenas uma oval.  
 
 Sim  
 Não. 3D Bioprinting é totalmente inovadora    Pare de preencher este formulário. 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
21. Indique qual é a tecnologia: * 
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Appendice 2 English Survey 
  
Emerging technology as new-life style. 3D Bioprinting 
a new era for innovation process 
 
This survey is restricted  only for medical students. 
 
I´m a student at the Faculty of Engineering of University of Porto. I am currently doing a Master thesis related 
with 3D Bioprinting technology, which can be considered an invention of sec: XXI not only in modern medicine 
but as well as in the “State of Art” of innovation process. 
 
Nowadays combining the basis of health with the high technological capability it is possible to print human 
tissue, using as ink human cells. 
 
The subject will focus on the mass reproduction of human organs, criteria, predictions, questions, all this will 
be analysis base in question. 
 
Therefore your help is essential, only 5 minutes can make the difference. 
 
*Mandatory 
 
 
1.Gender ?*   
Mark only one oval.  
 
 Masculino  
 Feminino 
 
2.Age? *  
 
 
 
 
3.Which University are you attending? *   
Mark only one oval..  
 
 Faculty of Medicine of University of Porto After the last question in this section, go to 
question 8 
 
 Faculty of Medicine Of University of Lisbon After the last question in this section, go 
to question 8 
 Faculty of Medicine of University of Coimbra After the last question in this section, 
go to question 8 
 Institute of Biomedical Sciences Abel Salazar of U.Porto After the last question in 
this section, go to question 8 
 Faculty of Medical Sciences of Lisbon After the last question in this section, go to 
question 8 
 Faculty of Medicine of University of Minho After the last question in this section, go 
to question 8 
 Faculty of Health Sciences of the University of Beira Interior After the last question 
in this section, go to question 8 
 Algarve University After the last question in this section, go to question 8 
 Other After the last question in this section, go to question 7 
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            4.In what academical phase are you in? *   
Make only one oval.  
 
 1º year    After the last question in this section, go to question 8.  
 2º year    After the last question in this section, go to question 8.  
 3º year    After the last question in this section, go to question 8. 
 4º year    After the last question in this section, go to question 8.  
 5º year    After the last question in this section, go to question 8.  
 6º year    After the last question in this section, go to question 8.  
 Common year   After the last question in this section, go to question 8. 
 1º year / Specialty  After the last question in this section, go to question 8. 
 2º year / Specialty  After the last question in this section, go to question 8. 
 3º year / Specialty  After the last question in this section, go to question 8 
 4º year / Specialty  After the last question in this section, go to question 8. 
 Other higher level  After the last question in this section, go to question 6. 
 
5.Specialty (If you don´t know the answer please 
say “ I do not know”)  
Please specify which one:  
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
6. Can you mention another academical phase, please? * 
 
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
7. Please refer other University? * 
 
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
8. Have you ever heard about 3D Bioprinting? *   
Mark only one oval.  
 
 Yes    Go to question 9.  
 No    Go to question 10. 
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Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
  
 
9.In which context? *   
More than one option can be choose.  
 
At the class 
 
Books, newspaper, magazine 
 
Television, Internet 
 
Through friends, colegues 
 
Other 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
10. 3D Bioprinting could be an answer for Transplants? *   
Refer the level of importance by using the scale   
Mark only one oval.  
 
0 1    2    3    4    5 
 
 
 
 
11.3D Bioprinting could be an answer for new drugs investigation*   
Refer the level of importance by using the scale  
Mark only one oval.  
 
0 1    2    3    4    5 
 
 
 
 
 
12. According to the previous answer, please mention in which situation 3D Bioprinting could be an 
asset: *  
Beware in which answer you will choose   
Mark only one oval.  
 
 University environment (Practical classes)  
 Only for transplants  
 Only for new drugs (Investigation)  
 Transplants and new drugs investigation  
 None of above 
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Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
13.What is your prediction for the 3D Bioprinting technology can be used? *   
Mark only one oval.  
 
 5-10 years  
 20-40 years  
 Next century  
 Never 
 
 
 
14.Possible constrains of 3D Bioprinting could be through *   
Mark more than one if you want.  
 
Human mentality 
 
Need 
 
Bureaucratic processes 
 
Ethics issues 
 
Religion 
 
Politics 
 
Economy 
 
None of above 
 
 
15.As a future Doctor, do you agreed with the use of 3D Bioprinting? *   
From the point of view of its acceptance   
Mark only one oval.  
 
 Yes    Go to queston 17.  
 No    Go to question 16. 
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
16.If you don´t agreed, please refer why? *  
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
17.Do you agreed with 3D Bioprinting in mass production *   
From the point of view of its use  
Mark only one oval.  
 
 Yes    Go to question 19.  
 No    Go to question 18. 
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Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
18.If you don´t agreed, please refer why? *  
 
 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
19.Do you agree with this quote " 3D Bioprinting is the future of modern medicine" *   
Mark only one oval.  
 
 Yes    After the last question in this section, go to question 21.  
 No    After the last question in this section, go to question 21. 
 
 
 
20.From your view does 3D Bioprinting can be replaced by any other techonology *   
Mark only one oval.  
 
 Yes  
 No. 3D Bioprinting is completely innovative 
 
Master in Innovation and Technological Entrepreneurship  
(FEUP-FEP) 
 
 21. Which technology can replace 3D Bioprinting: * 
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